Modern active surveillance in low- and intermediate-risk prostate cancer without re-biopsy

Jale Lakes¹, Rouvier Al-Monajjed^{1

2}, Isabelle Busshoff¹, Anne Hübner¹, Matthias Boschheidgen³, Birte Valentin³, Gerald Antoch^{3

4}, Peter Albers^{1

2}, Lars Schimmöller^{3

5}, Jan Philipp Radtke^{6

7}

Affiliations

¹ Department of Urology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany.
² Division of Personalized Early Detection of Prostate Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
³ Department of Diagnostic and Interventional Radiology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany.
⁴ Center for Integrated Oncology Düsseldorf (CIO Aachen, Bonn, Cologne, Düsseldorf), CIO, Düsseldorf, Germany.
⁵ Department of Diagnostic, Interventional Radiology and Nuclear Medicine, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.
⁶ Department of Urology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany. janphilipp.radtke@med.uni-duesseldorf.de.
⁷ Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. janphilipp.radtke@med.uni-duesseldorf.de.

Review

Jale Lakes et al. Prostate Cancer Prostatic Dis. 2025.

. 2025 Sep 14.

doi: 10.1038/s41391-025-01010-6. Online ahead of print.

¹ Department of Urology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany.
² Division of Personalized Early Detection of Prostate Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
³ Department of Diagnostic and Interventional Radiology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany.
⁴ Center for Integrated Oncology Düsseldorf (CIO Aachen, Bonn, Cologne, Düsseldorf), CIO, Düsseldorf, Germany.
⁵ Department of Diagnostic, Interventional Radiology and Nuclear Medicine, Marien Hospital Herne, University Hospital of the Ruhr-University Bochum, Herne, Germany.
⁶ Department of Urology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany. janphilipp.radtke@med.uni-duesseldorf.de.
⁷ Department of Radiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. janphilipp.radtke@med.uni-duesseldorf.de.

No abstract available

Conflict of interest statement

Competing interests: The authors declare no competing interests.

1. Cornford P, Tilki D, van den Bergh RCN, Briers E, Eberli D, De Meerleer G EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025. 2025.
1. Scheffer E, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW et al. NCCN clinical practice guidelines in oncology prostate cancer version 1. 2025.
1. Guideline Program Oncology (German Cancer Society, German Cancer Aid, AWMF): S3 Guideline Prostate Cancer, Long Version 8.01, 2025, AWMF Registry Number: 043-022OL. https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/ ; Accessed on [27.04.2025].
1. Lee JK, Assel M, Thong AE, Sjoberg DD, Mulhall JP, Sandhu J, et al. Unexpected long-term improvements in urinary and erectile function in a large cohort of men with self-reported outcomes following radical prostatectomy. Eur Urol. 2015;68:899–905. - DOI - PubMed - PMC
1. Maggi M, Cowan JE, Fasulo V, Washington SL, Lonergan PE, Sciarra A, et al. The long-term risks of metastases in men on active surveillance for early-stage prostate cancer. J Urol. 2020;204:1222–8. - DOI - PubMed